This study benefited from generous support by the American Psychiatric Foundation (APF) and an unrestricted educational grant to APF for this research by a consortium of industry supporters, including AstraZeneca International, Eli Lilly and Company, Lilly Foundation, Forest Laboratories, Pfizer, Sanofi Aventis, and Wyeth. The authors acknowledge significant contributions of the 17 psychiatric practices that participated in this project (see appendix at ps.psychiatryonline.org). Dr. Katzelnick is a principal shareholder of stock in Healthcare Technology Systems. Dr. Trivedi has received research support from the Agency for Healthcare Research and Quality (AHRQ), Corcept Therapeutics, Inc., Cyberonics, Inc., Merck, Naurex, Novartis, Pharmacia & Upjohn, Predix Pharmaceuticals (Epix), Solvay Pharmaceuticals, Inc., Targacept, and Valient. He has received consulting and speaker fees from Abbott Laboratories, Inc., Abdi Ibrahim, Akzo (Organon Pharmaceuticals Inc.), Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Evotec, Fabre Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica Products, Libby, LP, Johnson & Johnson PRD, Eli Lilly & Company, Meade Johnson, Medtronic, Neuronetics, Otsuka Pharmaceuticals, Parke-Davis Pharmaceuticals, Inc., Pfizer Inc., Sepracor, SHIRE Development, Sierra, Tal Medical/Puretech, Transcept, VantagePoint, and Wyeth-Ayerst Laboratories.